TransCode Therapeutics (NASDAQ:RNAZ) Given “Buy” Rating at HC Wainwright

Posted by Joseph Casey on Nov 16th, 2024

HC Wainwright reaffirmed their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock.

TransCode Therapeutics Trading Down 2.9 %

RNAZ traded down $0.01 during trading on Friday, hitting $0.34. The company’s stock had a trading volume of 264,385 shares, compared to its average volume of 1,253,209. TransCode Therapeutics has a twelve month low of $0.22 and a twelve month high of $18.66. The firm’s 50 day moving average price is $0.49 and its 200-day moving average price is $0.69.

TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.16). As a group, analysts forecast that TransCode Therapeutics will post -2.06 EPS for the current year.

Institutional Investors Weigh In On TransCode Therapeutics

An institutional investor recently raised its position in TransCode Therapeutics stock. Sheets Smith Wealth Management lifted its holdings in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) by 149.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 50,138 shares of the company’s stock after buying an additional 30,000 shares during the period. Sheets Smith Wealth Management owned 0.29% of TransCode Therapeutics worth $29,000 at the end of the most recent reporting period.

TransCode Therapeutics Company Profile

(Get Free Report)

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.